Repotrectinib increases effectiveness of MEK inhibitor trametinib in KRAS mutant cancer models via simultaneous SRC/FAK/JAK2 inhibition

被引：2
|
作者：
Murray, Brion [1 ]
Deng, Wei [1 ]
Zhai, Dayong [1 ]
Rodon, Laura [1 ]
Lee, Nathan [1 ]
Cui, J. Jean [1 ]
机构：
[1] Turning Point Therapeut Inc, San Diego, CA USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-1957
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1957
引用
收藏
页数：2
相关论文
共 17 条
  • [1] Repotrectinib increases KRAS-G12C inhibitor effectiveness via simultaneous inhibition of SRC, FAK, and JAK2
    Murray, B.
    Deng, W.
    Zhai, D.
    Lee, N. V.
    Rodon, L.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S39 - S40
  • [2] Repotrectinib increases effectiveness of KRAS-G12C inhibitors in KRAS-G12C mutant cancer models via simultaneous SRC/FAK/JAK2 inhibition
    Cui, J. Jean
    Zhai, Dayong
    Deng, Wei
    Rodon, Laura
    Lee, Nathan
    Murray, Brion
    CANCER RESEARCH, 2020, 80 (16)
  • [3] Repotrectinib increases effectiveness of MEK inhibitors in KRAS mutant cancer models.
    Lee, Nathan V.
    Deng, Wei
    Zhai, Dayong
    Rodon, Laura
    Parra, Ana
    Cowell, Jessica
    Banisadr, Afsheen
    Zhang, Xin
    Murray, Brion W.
    CANCER RESEARCH, 2021, 81 (13)
  • [4] Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
    Miyazaki, Satoru
    Kitazawa, Masato
    Nakamura, Satoshi
    Koyama, Makoto
    Yamamoto, Yuta
    Hondo, Nao
    Kataoka, Masahiro
    Tanaka, Hirokazu
    Takeoka, Michiko
    Komatsu, Daisuke
    Soejima, Yuji
    MOLECULAR ONCOLOGY, 2025, 19 (02) : 377 - 390
  • [5] Co-treatment of trametinib (MEK inhibitor) with TPX-0005 (Src/FAK/JAK2 inhibitor) synergistic in KRAS mutant NSCLC cell lines and CDCP1 acts as a biomarker in KRAS mutant patients (p)
    Codony-Servat, C.
    Gil Moreno, M. Llanos
    Bracht, J.
    Attili, I.
    Lazzari, C.
    Gregorc, V.
    Ito, M.
    Viteri, S.
    Karachaliou, N.
    Rosell, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S30 - S31
  • [6] Identification of JAK2/STAT3 as a novel therapeutic target in Kras mutant colorectal cancer models
    Kalimutho, M.
    Carson, R.
    Dunne, P.
    Longley, D.
    Johnston, P.
    Van Schaeybroeck, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S9 - S9
  • [7] PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
    Kauko, Otto
    O'Connor, Caitlin M.
    Kulesskiy, Evgeny
    Sangodkar, Jaya
    Aakula, Anna
    Izadmehr, Sudeh
    Yetukuri, Laxman
    Yadav, Bhagwan
    Padzik, Artur
    Laajala, Teemu Daniel
    Haapaniemi, Pekka
    Momeny, Majid
    Varila, Taru
    Ohlmeyer, Michael
    Aittokallio, Tero
    Wennerberg, Krister
    Narla, Goutham
    Westermarck, Jukka
    SCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (450)
  • [8] JAK2 TYROSINE KINASE INHIBITOR AG490 SUPPRESSES CELL GROWTH AND INVASION OF GALLBLADDER CANCER CELLS VIA INHIBITION OF JAK2/STAT3 SIGNALING
    Fu, L-X.
    Lian, Q-W.
    Pan, J-D.
    Xu, Z-L.
    Zhou, T-M.
    Ye, B.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2017, 31 (01): : 51 - 58
  • [9] A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
    Blumenschein, G. R., Jr.
    Smit, E. F.
    Planchard, D.
    Kim, D. -W.
    Cadranel, J.
    De Pas, T.
    Dunphy, F.
    Udud, K.
    Ahn, M. -J.
    Hanna, N. H.
    Kim, J. -H.
    Mazieres, J.
    Kim, S. -W.
    Baas, P.
    Rappold, E.
    Redhu, S.
    Puski, A.
    Wu, F. S.
    Jaenne, P. A.
    ANNALS OF ONCOLOGY, 2015, 26 (05) : 894 - 901
  • [10] A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS-mutant (KRAS-MT) non-small cell lung cancer (NSCLC)
    Camidge, D. Ross
    Pachter, Jonathan
    Koustenis, Andrew
    Patrick, Gloria
    Spigel, David R.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
12